NME Approvals Show Early Impact From MedGuide/REMS Guidance
You may also be interested in...
Eliminating MedGuide-Only REMS Merits PDUFA-Style Deadlines, PhRMA Says
FDA should take no more than three months deciding whether a Medication Guide can be pulled out of an existing Risk Evaluation and Mitigation Strategy, the Pharmaceutical Research and Manufacturers of America believes.
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.